PURE Bioscience Management
Management criteria checks 4/4
PURE Bioscience's CEO is Robert Bartlett, appointed in Mar 2023, has a tenure of 2.75 years. total yearly compensation is $191.30K, comprised of 79.4% salary and 20.6% bonuses, including company stock and options. directly owns 0.045% of the company’s shares, worth $2.32K. The average tenure of the management team and the board of directors is 2.9 years and 4.9 years respectively.
Key information
Robert Bartlett
Chief executive officer
US$191.3k
Total compensation
| CEO salary percentage | 79.40% |
| CEO tenure | 2.8yrs |
| CEO ownership | 0.04% |
| Management average tenure | 2.9yrs |
| Board average tenure | 4.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Oct 31 2025 | n/a | n/a | -US$2m |
| Jul 31 2025 | US$191k | US$152k | -US$2m |
| Apr 30 2025 | n/a | n/a | -US$3m |
| Jan 31 2025 | n/a | n/a | -US$3m |
| Oct 31 2024 | n/a | n/a | -US$3m |
| Jul 31 2024 | US$215k | US$200k | -US$3m |
| Apr 30 2024 | n/a | n/a | -US$4m |
| Jan 31 2024 | n/a | n/a | -US$4m |
| Oct 31 2023 | n/a | n/a | -US$4m |
| Jul 31 2023 | US$130k | US$109k | -US$4m |
Compensation vs Market: Robert's total compensation ($USD191.30K) is below average for companies of similar size in the US market ($USD575.90K).
Compensation vs Earnings: Robert's compensation has been consistent with company performance over the past year.
CEO
Robert Bartlett (80 yo)
Mr. Robert F. Bartlett served as an Independent Director of PURE Bioscience, Inc. since February 08, 2023 until March 15, 2023 and serves as its Director since March 15, 2023 and was President from March 1...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.8yrs | US$191.30k | 0.045% $ 2.3k | |
| VP of Finance and Principal Financial & Accounting Officer | 10.4yrs | US$178.60k | 0.065% $ 3.3k | |
| Executive VP of Technology & Development and Director | 2.9yrs | US$197.40k | 0.76% $ 39.4k | |
| President & Corporate Secretary | 6.9yrs | no data | 0.012% $ 602.0 | |
| Vice President of Operations & & Regulatory Affairs | less than a year | no data | no data | |
| Vice President of Sales & Marketing | no data | no data | no data |
Experienced Management: PURE's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.8yrs | US$191.30k | 0.045% $ 2.3k | |
| Executive VP of Technology & Development and Director | 4.9yrs | US$197.40k | 0.76% $ 39.4k | |
| Member of Scientific Advisory Board | 5yrs | no data | no data | |
| Director | 11.2yrs | US$29.50k | 39.34% $ 2.0m | |
| Independent Chairman of the Board | 7.5yrs | US$36.53k | 0.67% $ 34.7k | |
| Independent Director | 4.9yrs | US$32.50k | 0.36% $ 18.6k | |
| Member of Scientific Advisory Board | 5.3yrs | no data | no data | |
| Independent Director | 2.8yrs | US$32.50k | 0.0089% $ 463.1 | |
| Independent Director | 1.6yrs | US$32.00k | no data |
Experienced Board: PURE's board of directors are considered experienced (4.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/25 15:20 |
| End of Day Share Price | 2025/12/23 00:00 |
| Earnings | 2025/10/31 |
| Annual Earnings | 2025/07/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PURE Bioscience, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Keith Markey | Griffin Securities |